Nut and Peanut Hypersensitivity: Clinical Trials

44 trials for Nut and Peanut Hypersensitivity, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

27 completed, 6 recruiting, 6 terminated, 3 withdrawn. 44 Phase 1, 22 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 144Completed 27, Recruiting 6, Terminated 6, Withdrawn 3, Active not recruiting 1, Suspended 1
Phase 222Completed 12, Recruiting 4, Terminated 4, Withdrawn 2

Follow Nut and Peanut Hypersensitivity: new trials by email Literature Review of Nut and Peanut Hypersensitivity trials Research Report on Nut and Peanut Hypersensitivity

Trials (filtered) newest first · largest first

All 44 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety of MOON101 for the Treatment of Peanut Allergy
Dose A, Dose B, Dose C - Peanut Allergy
Phase 1SuspendedMoonlight Therapeutics, Inc.402026-06-292026-10-16
Single Ascending and Multiple Ascending Dose Study of LCA-0061
LCA-0061, Placebo - Atopic Disease, Peanut Allergies
Phase 1RecruitingLycia Therapeutics, Inc.722026-06-262026-07-14
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy
Phase 1WithdrawnCandid Therapeutics2026-04-012026-07-22
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
UKK-0018 - Peanut-Induced Anaphylaxis, Peanut Allergy
Phase 1 / Phase 2RecruitingUkko Inc402026-02-182026-10-16
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
ENP-501, Placebo - Peanut Allergy
Phase 1 / Phase 2RecruitingN-Fold, LLC682025-12-162026-04-24
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
MY006 Low Dose, MY006 Mid Dose, MY006 High Dose - Peanut Allergies
Phase 1RecruitingMabylon AG482025-12-062026-10-20
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray - Food Allergy, Anaphylaxis
Phase 1CompletedInsignis Therapeutics, Inc.322025-10-242026-05-05
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001
IGNX001, Placebo - Peanut Allergy
Phase 1CompletedIgGenix Australia Pty Ltd322024-09-012025-11-14
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
VLP Peanut, Placebo - Peanut Allergy
Phase 1Active not recruitingAllergy Therapeutics462022-10-172026-03-13
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
Peanut SLIT-tablet, Placebo - Peanut Allergy
Phase 1 / Phase 2CompletedALK-Abelló A/S2092022-09-072026-05-11
Open-label Extension Study of ADP101
ADP101 - Food Allergy
Phase 1 / Phase 2TerminatedAlladapt Immunotherapeutics, Inc.452022-03-142024-03-26
CNP-201 in Subjects With Peanut Allergy
CNP-201, Placebo - Peanut Allergy
Phase 1TerminatedCOUR Pharmaceutical Development Company, Inc.152022-03-142023-12-20
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
Prebiotic, Placebo - Peanut Allergy
Phase 1 / Phase 2CompletedUniversity of Chicago202021-11-302026-03-09
Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy
CNP-201, Placebo - Peanut Allergy
Phase 1TerminatedCOUR Pharmaceutical Development Company, Inc.92021-06-022023-09-18
OMEGA Study: A Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut
INT301, Placebo - Peanut Allergy
Phase 1CompletedIntrommune Therapeutics322021-05-152023-07-28
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Low dose ADP101, High dose ADP101, Pooled Placebo - Food Allergy
Phase 1 / Phase 2CompletedAlladapt Immunotherapeutics, Inc.732021-04-202024-05-16
Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy
Peanut allergen - Food Allergy Peanut
Phase 1 / Phase 2WithdrawnScripps Health2021-03-012022-11-22
Oral Immunotherapy for Peanut Allergic Patients
INP20, Placebo - Peanut Allergy
Phase 1 / Phase 2RecruitingInnoUp Farma S.L.502020-03-112025-04-30
Boiled Peanut Oral Immunotherapy
Boiled Peanut Powder - Peanut Hypersensitivity
Phase 1CompletedAlton Melton82019-11-052024-09-19
VE416 for Treatment of Food Allergy
Vancomycin plus VE416 before PNOIT, Vancomycin plus VE416 with PNOIT, Placebo plus VE416 with PNOIT - Peanut Allergy
Phase 1 / Phase 2RecruitingMassachusetts General Hospital602019-06-282023-10-18

Showing 20 of 44. Sign in to see all of them.

Narrower conditions

Peanut Hypersensitivity (42)  ·  Food Hypersensitivity (20)  ·  Hypersensitivity (10)  ·  Hypersensitivity, Immediate (7)  ·  Nut Hypersensitivity (6)  ·  Anaphylaxis (4)  ·  Egg Hypersensitivity (3)  ·  Milk Hypersensitivity (3)  ·  Wheat Hypersensitivity (3)  ·  Immune System Diseases (2)  ·  Shellfish Hypersensitivity (2)  ·  Asthma (1)  ·  Dermatitis, Atopic (1)  ·  Rhinitis, Allergic (1)  ·  Rhinosinusitis (1)

Broader conditions

Immune System Diseases (42)  ·  Hypersensitivity, Immediate (37)  ·  Hypersensitivity (34)  ·  Food Hypersensitivity (24)  ·  Bronchial Diseases (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Dermatitis (1)  ·  Genetic Diseases, Inborn (1)  ·  Infections (1)  ·  Lung Diseases (1)  ·  Lung Diseases, Obstructive (1)  ·  Nose Diseases (1)  ·  Otorhinolaryngologic Diseases (1)  ·  Paranasal Sinus Diseases (1)

Interventions

Omalizumab (3)  ·  Epinephrine (1)  ·  Fecal Microbiota Transplantation (1)  ·  Glycerol (1)  ·  Immunotherapy (1)  ·  Needles (1)  ·  Prebiotics (1)  ·  Vancomycin (1)

Sponsors

University of North Carolina, Chapel Hill (5)  ·  Alladapt Immunotherapeutics, Inc. (2)  ·  Astellas Pharma Global Development, Inc. (2)  ·  COUR Pharmaceutical Development Company, Inc. (2)  ·  DBV Technologies (2)  ·  HAL Allergy (2)  ·  Johns Hopkins University (2)  ·  Massachusetts General Hospital (2)  ·  ALK-Abelló A/S (1)  ·  Allergy Therapeutics (1)  ·  Allertein Therapeutics, LLC (1)  ·  Alton Melton (1)  ·  Baylor College of Medicine (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Boston Children's Hospital (1)

Countries

United States (35)  ·  Australia (3)  ·  Canada (3)  ·  Denmark (1)  ·  New Zealand (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Wesley Burks, MD (5)  ·  Edwin Kim, MD (4)  ·  Robert Wood, MD (4)  ·  Jerry Staser (2)  ·  Mei-Lun Wang, MD (2)  ·  Scott Sicherer, MD (2)  ·  Wayne G Shreffler, MD, PhD (2)  ·  Ana Tabar, PhD, MD (1)  ·  Andrew MacGinnitie, MD, PhD (1)  ·  Andrew T Clark, MB BD MD (1)  ·  Brian P Vickery, MD (1)  ·  Carla M Davis, MD (1)  ·  Carsten Bindslev-Jensen, Prof. Dr. (1)  ·  Christina E Ciaccio, MD (1)  ·  Corinne Keet, MD, MS (1)

Results publications

PMID 32414772, PMID 33463542, PMID 38010254, PMID 19226304, PMID 21414048, PMID 23265698, PMID 25528358, PMID 25656999, PMID 26920463, PMID 29700872, PMID 31676085, PMID 34755130, PMID 34813505, PMID 39756833, PMID 39842774

NIH funding

2018 (1), R01AT004435 (1), U19AI095261 (1), U44AI165328 (1)